Daniel H. Schneiderman - 03 Jan 2022 Form 4 Insider Report for First Wave BioPharma, Inc. (ENTO)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: ENTO
Reported as of: 03 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2022, 20:07:07 UTC
Prior SEC filing: 02 Jul 2021
Next SEC filing: 15 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Daniel H. Schneiderman

Key filing fact

Daniel H. Schneiderman filed Form 4 for First Wave BioPharma, Inc. (ENTO) on 03 Jan 2022.

Key facts

This page summarizes Daniel H. Schneiderman's Form 4 filing for First Wave BioPharma, Inc. (ENTO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2022, 20:07.

Change

Previous filing in this sequence was filed on 02 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FWBI transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 03 Jan 2022
Ownership: Direct
Underlying class: Common stock, par value $0.0001 per share
Underlying amount: 10,000
Exercise price: $1.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Schneiderman's continued employment by First Wave BioPharma, Inc. on the applicable vesting date.